Background: Bacterial resistance to antibiotics is a growing therapeutic problem, both in the community and the hospitals, which involves all the antibiotics including fuoroquinolones. The decreased susceptibility to fuoroquinolones arises mainly due to single-step mutations in the gyrA and the parC genes, which encode the fuoroquinolones targets, the topoisomerase enzymes, thus conferring cross-resistance to the fuoroquinolones. In 1998, some mobile elements with a potential for the horizontal transfer of the quinolone resistance genes were described. The loci which are responsible for this plasmid-mediated quinolone resistance, which have been designated as qnr A, qnr B and qnr S, have been identifed in the Enterobacteriaceae species. Aim: This study was undertaken to evaluate the susceptibility pattern of the isolates to various antibiotics and to know the prevalence rate of ciprofoxacin resistance in our hospital. Materials & Methods: A total of 734 gram-negative bacilli (GNB) which were isolated from various clinical samples over a period of six months, were subjected to antibiotic susceptibility testing. Isolates with resistance or with a decreased susceptibility to ciprofoxacin (≤20 mm) were then screened for their minimum inhibitory concentration (MIC) by using the E-test. Results: Out of 734 GNB, 235 (32%) isolates were resistant to ciprofoxacin. The MIC of these isolates ranged from 4 to > 32μg/ml. Conclusion: The resistance rate to ciprofoxacin was 32% in our study. Most of the ciprofoxacin resistant isolates were from urinary tract infections (UTI). The ciprofoxacin resistance was also closely associated with multi-drug resistance, thus limiting the treatment options. Ciprofoxacin resistance can be used as a general surrogate marker of multidrug resistance, thus limiting the already restricted treatment options. The considerably high MIC values for ciprofoxacin in this study refected the extent of the treatment problems for these resistant isolates and a need for the continuous evaluation of the commonly used antibiotics. © 2020 Elsevier B.V., All rights reserved.